Program
tucidinostat
Also written as “Chidamide”, “Tucidinostat” and “HBI-8000”.
Its studies are mostly in Lymphoma, T-Cell, Peripheral · Carcinoma, Non-Small-Cell Lung · Melanoma · Breast Neoplasms · Lymphoma, Non-Hodgkin, led by 4 companies.
Drug pageTucidinostat: every studyAll 185 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Chipscreen Biosciencesits history only | 92 open or running | phase 3since Jun 17, 2015 | Apr 12, 2013 | May 31, 2028phase 3 · NCT06497985 |
| HUYABIO International, LLC.its history only | 71 open or running | phase 3since Dec 7, 2020 | Oct 5, 2015 | none ahead |
| Great Novel Therapeutics Biotech & Medicalsits history only | 21 open or running | phase 2since Feb 7, 2023 | Feb 7, 2023 | Jun 2027phase 2 · NCT05833724 |
| Jiangsu HengRui Medicineits history only | 11 open or running | phase 3since Nov 5, 2023 | Nov 5, 2023 | none ahead |
Also a collaborator on its studies: Bristol-Myers Squibb and Iqvia Pty.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 4 studies since Apr 12, 2013.
- Mar 15, 2016Phase 2 study in MelanomaHUYABIO International, LLC. · NCT02718066 · 96 enrolled · United States
- Jun 9, 2016Named tucidinostatINNProposed as its International Nonproprietary Name in WHO's List 115 · before, HBI-8000
- Jun 17, 2016Phase 1 study in Lymphoma, T-Cell, PeripheralChipscreen Biosciences · NCT02809573 · 30 enrolled · China
- Nov 1, 20162 phase 2 studiesHUYABIO International, LLC. · NCT02955589, NCT02953652
- May 30, 2019Phase 2 study in Lymphoma, Non-HodgkinChipscreen Biosciences · NCT03974243 · 9 enrolled · China
- Jan 14, 2020Phase 3 study in Lymphoma, Large B-Cell, DiffuseChipscreen Biosciences · NCT04231448 · 423 enrolled · China
- Dec 7, 2020Phase 3 study in MelanomaHUYABIO International, LLC. · NCT04674683 · 450 enrolled · United States, Australia, Austria and more
- Sep 27, 2021Phase 2 study in Carcinoma, Non-Small-Cell LungChipscreen Biosciences · NCT05068427 · 34 enrolled · China
- Nov 19, 2021Phase 2 study in Carcinoma, Non-Small-Cell LungHUYABIO International, LLC. · NCT05141357 · 5 enrolled · United States
- Aug 23, 2022Phase 2 study in Carcinoma, Non-Small-Cell LungChipscreen Biosciences · NCT05519865 · 118 enrolled · China
- Feb 7, 2023Great Novel Therapeutics Biotech & Medicals’ first study: phase 2 study in Carcinoma, HepatocellularNew to Great Novel Therapeutics Biotech & MedicalsGreat Novel Therapeutics Biotech & Medicals · NCT05770882 · 7 enrolled · Taiwan
- Apr 17, 2023Phase 2 study in RecurrenceGreat Novel Therapeutics Biotech & Medicals · NCT05833724 · 33 planned · Taiwan
- Nov 5, 2023Jiangsu HengRui Medicine’s first study: phase 3 study in RecurrenceNew to Jiangsu HengRui MedicineJiangsu HengRui Medicine · NCT06122389 · 130 planned · China
- Jun 28, 2024Phase 3 study in Colorectal NeoplasmsChipscreen Biosciences · NCT06497985 · 430 planned · China
- Apr 25, 2025Phase 3 study in Lymphoma, T-Cell, PeripheralChipscreen Biosciences · NCT06947967 · 224 planned · China
Ahead
- Jun 2027Primary completion: phase 2 study in RecurrenceGreat Novel Therapeutics Biotech & Medicals · NCT05833724
- May 31, 2028Primary completion: phase 3 study in Colorectal NeoplasmsChipscreen Biosciences · NCT06497985
- Dec 2032Primary completion: phase 3 study in Lymphoma, T-Cell, PeripheralChipscreen Biosciences · NCT06947967
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 19 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06947967Lymphoma, T-Cell, Peripheral · China | 3 | Recruiting | Chipscreen Biosciences | Dec 2032 | 224 |
| NCT06497985Colorectal Neoplasms · China | 3 | Recruiting | Chipscreen Biosciences | May 31, 2028 | 430 |
| NCT06122389Recurrence · China | 3 | Recruiting | Jiangsu HengRui Medicine | May 2026 | 130 |
| NCT05833724Recurrence · Taiwan | 2 | Recruiting | Great Novel Therapeutics Biotech & Medicals | Jun 2027 | 33 |
| NCT05770882Carcinoma, Hepatocellular · Taiwan | 2 | Terminated | Great Novel Therapeutics Biotech & Medicals | Jan 17, 2025 | 7 |
| NCT05519865Carcinoma, Non-Small-Cell Lung · China | 2 | Completed | Chipscreen Biosciences | Nov 18, 2024 | 118 |
| NCT05141357Carcinoma, Non-Small-Cell Lung · United States | 2 | Terminated | HUYABIO International, LLC. | Apr 19, 2023 | 5 |
| NCT05068427Carcinoma, Non-Small-Cell Lung · China | 2 | Completed | Chipscreen Biosciences | Feb 23, 2023 | 34 |
| NCT04674683Melanoma · United States, Australia, Austria and more | 3 | Active, not recruiting | HUYABIO International, LLC. | Jul 2026 | 450 |
| NCT04231448Lymphoma, Large B-Cell, Diffuse · China | 3 | Completed | Chipscreen Biosciences | Jan 10, 2023 | 423 |
| NCT03974243Lymphoma, Non-Hodgkin · China | 2 | Completed | Chipscreen Biosciences | Dec 31, 2021 | 9 |
| NCT02955589Precursor T-Cell Lymphoblastic Leukemia-Lymphoma · Japan | 2 | Completed | HUYABIO International, LLC. | Dec 2018 | 23 |
| NCT02953652Lymphoma, T-Cell, Peripheral · Japan, Korea, Republic of | 2 | Completed | HUYABIO International, LLC. | Feb 17, 2022 | 55 |
| NCT02809573Lymphoma, T-Cell, Peripheral · China | 1 | Completed | Chipscreen Biosciences | Jan 8, 2019 | 30 |
| NCT02718066Melanoma · United States | 2 | Completed | HUYABIO International, LLC. | Dec 12, 2023 | 96 |
| NCT02697552Lymphoma, Non-Hodgkin · Japan | 1 | Completed | HUYABIO International, LLC. | Oct 2016 | 13 |
| NCT02569489Breast Neoplasms | 1 | Withdrawn | HUYABIO International, LLC. | Dec 2015 | 0 |
| NCT02482753Breast Neoplasms · China | 3 | Completed | Chipscreen Biosciences | Mar 2018 | 365 |
| NCT01836679Carcinoma, Non-Small-Cell Lung · China | 2 | Completed | Chipscreen Biosciences | May 2015 | 124 |
How it is read
Names in the registry
- “Chidamide”, 7 entries
- “Tucidinostat”, 4 entries
- “HBI-8000”, 4 entries
- “HBI-8000 in combination with nivolumab”, 2 entries
- “SHR2554 analog tablets; Chidamide”, 1 entry
Conditions, from the studies’ own filings
- Lymphoma, T-Cell, Peripheral, 4 studies
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Melanoma, 2 studies
- Breast Neoplasms, 2 studies
- Lymphoma, Non-Hodgkin, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.